Compositions comprising amphotericin B, methods, and systems
View Patent ↗A composition includes particles including at least about 95 wt % of amphotericin B, wherein the particles have a mass median diameter ranging from about 1.1 μm to about 1.9 μm. Another composition also includes particles including at least about 95 wt % of amphotericin B, wherein at least about 80 wt % of the particles have a geometric diameter ranging from about 1.1 μm to about 1.9 μm. Yet another composition includes particles including amphotericin B, wherein the particles have a mass median diameter less than about 1.9 μm, and wherein the amphotericin B has a crystallinity level of at least about 20%. Unit dosage forms, delivery systems, and methods may involve similar compositions.
1. A composition, for localized delivery to the lungs as a powder, the composition consisting essentially of:
particles comprising at least about 95 wt % of amphotericin B,
wherein the particles comprise a crystallinity level of at least about 20%, a mass median diameter from 1.1 μm to 1.9 μm, and wherein at least about 80 wt % of the particles have a geometric diameter from 1.1 μm to 1.9 μm.
2. The composition of claim 1 , wherein the amphotericin B has a crystallinity level of at least about 70%.
3. The composition of claim 1 , wherein the amphotericin B has a crystallinity level of at least about 90%.
4. The composition of claim 1 , wherein the amphotericin B has a crystallinity level ranging from about 50% to about 99%.
5. A composition, for localized delivery to the lungs as a powder, the composition consisting essentially of:
particles comprising at least about 95 wt % of amphotericin B, the amphotercin B comprising a crystallinity level of at least about 70%, and wherein at least 80 wt % of the particles have a geometric diameter from 1.1 μm to 1.9 μm.
6. The composition of claim 5 , wherein the amphotericin B has a crystallinity level of at least about 90%.